CAS: 2088-71-3; Testosterone 17-Benzoate

上下游产品

17β-benzoyloxy-androst-5-en-3-one 5α-hydroxy-3-oxo-5α-androstan-17β-yl benzoate testosterone benzoyl chloride17β-benzoyloxy-6β-bromo-androst-4-en-3-one 3,3-ethanediyldioxy-17β-benzoyloxy-androst-5-ene A-nor-androstan-3-oic acid17β-benzoyloxy-5-oxo-3,5-seco-A-nor-androstan-3-oic acid testosterone

📜17β-Benzoyloxy-Androst-5-En-3-One置于硫酸体系中,化学反应生成17-安息香酸雄烯醇酮
参考文献:Notes-The Direct Conversion Of Steroidal δ5-3β-Alcohols To δ5-And δ4-3-Ketones
标题:Notes-The Direct Conversion Of Steroidal δ5-3β-Alcohols To δ5-And δ4-3-Ketones
摘要:
Doi:10.1021/jo01118A627

专利信息

专利号:US-4219489-A
优先权日:1978-09-05
标题:Synthesis of steroids
发明人：BUNES LEONARD A; JOHNSON WILLIAM S
权利人:STANFORD LELAND JUNIOR UNIV TR
摘要:Method and compounds are provided for use in the synthesis of steroids wherein a polyolefin is provided having an initiating group having a chalcogen atom in juxtaposition to a double bond, so as to be capable of bond formation to close to form a ring and having a terminating group involving pi unsaturation (a double or triple bond) conjugated to an aromatic ring. Upon acid catalysis, sigma bonds are formed through the interaction of a carbocation formed at the carbon atom bonded to the chalcogen atom and the double bond intermediate the initiating group and the terminating group, which close to form rings of a steroid nucleus, the carbocation interacting with the pi unsaturation conjugated with the aromatic group and being captured by a nucleophile present in the acidic reaction medium. The resulting steroid product may then be modified in known ways to produce known steroids.

专利号:US-2025281509-A1
优先权日:2021-04-26
标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.